Pyrazinamide Market, by Patient Type (Adult and Pediatric), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2020 - 2027

Published In : Dec 2020

Code : CMI4317

Pages :149

Formats :

Excel and PDF

Industry : Pharmaceutical

Pyrazinamide MarketSize and Trends

The global pyrazinamide market is estimated to be valued at US$ 143.9 million in 2020 and is expected to exhibit a CAGR of 4.6% during the forecast period (2020-2027).

Fig. 1. Global Pyrazinamide Market Share (%) Analysis, By Patient Type, 2020

Market- Trends

The increasing tuberculosis (TB) disease prevalence is a major factor that is expected to drive growth of the global pyrazinamide market. For instance, according to the National Center for Biotechnology Information in 2019, total 8,920 number of TB disease new cases were provisionally reported in the U.S. according to same source, the rate of TB is around 2.7 per 100,000 persons. Moreover, TB is a major burden across the globe. According to TB Facts report organization data, in 2018, in the U.S, the cost of treating drug sensitive TB was US$ 49,000; treatment costs for MDR-TB averaged US$ 393,000; and treatment costs for XDR TB averaged US$ 758,000.

Global Pyrazinamide Market - Impact of Coronavirus (COVID-19) Pandemic

The spread of the novel coronavirus has hampered growth of the healthcare industry. In December 2019, a cluster of pneumonia cases were reported by Chinese health authorities in China’s Wuhan City. The pneumonia causative agent was identified as a novel coronavirus named COVID-19. This virus spread rapidly across the globe causing a concerning number of fatalities. In March, 2020, the World Health Organization (WHO) declared COVID-19 as a global pandemic and suggested implementation of strict measures to minimize the spread of this disease. The pandemic has slowed growth of the healthcare sector and led to a disturbance in the supply chain of pharmaceutical drugs.

Moreover, governments across various countries have implemented nationwide lockdowns to curb the spread of COVID-19. Similarly, in various countries across the world, healthcare companies are facing problems of continuing their supply chain operations. The slowdown of the supply chain has also impacted growth of the global pyrazinamide market.